10Q Detective

Investors often overlook SEC filings, and it is the job of the 10Q Detective to dig through businesses’ 8-K and 10-Q SEC filings, looking for financial statement ‘soft spots,'(depreciation policies, warranty reserves, and restructuring charges, etc.)that may materially impact Quality of Earnings.

Friday, March 30, 2007

USANA & MLM Schemes -- Pyramid Scheme Alert Speaks Out

›
The 10Q Detective is publishing in its entirety an articulate and educational letter that we just received on Usana Health Sciences & ML...
1 comment:
Tuesday, March 27, 2007

Long Live the AFLAC Duck!

›
Aflac Inc. (AFL-$47.64) , the largest provider of guaranteed-renewable insurance in the United States and Japan, rewarded Chairman and CEO ...
Thursday, March 22, 2007

USANA Health Sciences--How Healthy is its Business Model?

›
Last week, Barry Minkow (infamous for the 1980s ZZZ Best Scandal) and his Fraud Discovery Institute released a 500-page report on USANA ...
6 comments:
Tuesday, March 20, 2007

Something Smells at Bodisen Biotech--and it ain't Manure!

›
In January, China-based Bodisen Biotech Inc. (BBC-$3.36) , which produces fertilizers and pesticides, announced it expected to post a 74 per...
3 comments:

"Taking Stock with Derek Simon" Podcast

›
Last week, the 10Q Detective guested on istockanalyst.com, a virtual investment educational site and collection of tools to assist individua...
Friday, March 16, 2007

Looking for Profitable Ideas? Follow the "CalPERS' Effect."

›
Responding to dismal stock performance and poor governance practices, the California Public Employees’ Retirement System (CalPERS) , the nat...
Wednesday, March 14, 2007

Washing Machines, Cruises, and Tax Gross-ups -- Handouts Live On in Corporate Boardrooms.

›
Despite recently enacted SEC regulations that made reporting of executive compensation more transparent—and allegedly easier to read and dig...
1 comment:
Monday, March 12, 2007

Amkor Tech Facing Bumps in the Road Ahead?

›
From looking at Amkor Technology’s (AMKR-$12.02) regulatory filings, an investor can see the muddy footprints—for better or worse?—of the K...
Friday, March 09, 2007

Shareholders in Hollis-Eden Sickened by Neumune Failure

›
Drug developer Hollis-Eden Pharmaceuticals Inc. (HEPH-$2.90) said Thursday the Department of Health and Human Services rejected the company...
4 comments:
‹
›
Home
View web version

About Me

My photo
David J. Phillips
Prior to founding the 10Q Detective, I held equity analyst positions with three brokerage firms and published the investment newsletter e-Growth Profit Letter - dedicated to uncovering companies with innovative, proprietary technologies in a range of industries. My work has been published in The Dick Davis Digest, The Bull & Bear Financial Report, BusinessWeek, CBS Interactive, Forbes, Kiplingers Personal Finance, MSN Money, TheStreet.com, 24/7 Wall Street, The Wall St. Journal, The International Herald Tribune, and Investors Business Daily. The 10Q Detective is recommended as a 'Must-Read' money blog in Kiplingers (Oct. 2006 & May 2008), Washington Post (May 2009); a 'Best of Financial Blog' by BusinessWeek (Feb. 2007 & April 2008),a 'Smart Stop' by The Journal of Accountancy (March 2008); 'Top 25' by Time magazine, a 'Top 50 Money Blog' by CurrencyTrading.net (April 2008); and, a 2011 LexisNexis Business Law Blog Nominee.
View my complete profile
Powered by Blogger.